Article
Cardiac & Cardiovascular Systems
Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Darren K. Mcguire, Silvio E. Inzucchi, Renato D. Lopes, Michael J. Davies, Phillip Banks, Bertram Pitt, Philippe Gabriel Steg
Summary: This study assessed the efficacy of Sotagliflozin on heart failure clinical outcomes in individuals with different baseline glycosylated hemoglobin levels. The results showed that Sotagliflozin reduced heart failure outcomes, regardless of baseline HbA1c.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Endocrinology & Metabolism
Deven Juneja, Prashant Nasa, Ravi Jain, Omender Singh
Summary: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) may rarely lead to the development of euglycemic diabetic ketoacidosis (EDKA). This study analyzed the characteristics and outcomes of patients with EDKA secondary to SGLT2i use. It was found that the occurrence of this complication is low and mainly associated with severe acute infections and major surgeries.
WORLD JOURNAL OF DIABETES
(2023)
Review
Cardiac & Cardiovascular Systems
Yao Hao Teo, Yao Neng Teo, Nicholas L. Syn, Cheryl Shumin Kow, Celine Shuen Yin Yoong, Benjamin Y. Q. Tan, Tiong-Cheng Yeo, Chi-Hang Lee, Weiqin Lin, Ching-Hui Sia
Summary: SGLT2 inhibitors have shown positive effects on cardiovascular outcomes in patients without diabetes mellitus, particularly in reducing cardiovascular deaths and heart failure hospitalizations in heart failure patients. Additionally, these inhibitors have beneficial metabolic effects, such as weight and blood pressure control, in patients without diabetes mellitus.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Medicine, General & Internal
Yun Chin Wong, Kuan-Lin Liu, Chia-Ling Lee
Summary: Patients with type 2 diabetes (T2D) taking SGLT2 inhibitors should be aware of the risk of euglycemic diabetic ketoacidosis (euDKA) during the perioperative period, especially in emergency surgeries. It is important to promptly conduct ketonuria testing and blood tests to adjust treatment plans for these patients.
Review
Cardiac & Cardiovascular Systems
Boyang Xiang, Xiaoya Zhao, Xiang Zhou
Summary: Sodium-glucose cotransporter 2 inhibitors show beneficial cardiovascular effects independent of glycemic control, leading to their recommendation for use in cardiovascular diseases, potentially extending their therapeutic spectrum to nondiabetic patients.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Medicine, General & Internal
Mukul Bhattarai, Mohsin Salih, Manjari Regmi, Mohammad Al-Akchar, Radhika Deshpande, Zurain Niaz, Abhishek Kulkarni, Momin Siddique, Shruti Hegde
Summary: This meta-analysis supports the effectiveness of SGLT2 inhibitors in improving cardiovascular morbidity and mortality in selected patients. However, SGLT2 inhibitors were not associated with a reduced risk of acute myocardial infarction. Future long-term prospective studies are needed to further understand the long-term cardiovascular benefits.
Article
Medicine, General & Internal
Han Eol Jeong, Sohee Park, Yunha Noh, Sungho Bea, Kristian B. Filion, Oriana H. Y. Yu, Seung Hun Jang, Young Min Cho, Dong Keon Yon, Ju-Young Shin
Summary: This study examines the association between the use of SGLT2 inhibitors and the risk of adverse respiratory events in patients with type 2 diabetes. The results suggest a lower risk of respiratory events in patients initiating SGLT2 inhibitors compared to those initiating DPP4 inhibitors.
Article
Endocrinology & Metabolism
Bin Zhao, Juan Shen, Jun Zhao, Hui Pan
Summary: In this study investigating adverse events related to SGLT2is and fractures, it was found that while there was no association between SGLT2is or combined therapy with GLMs and fracture risk, SGLT2i-associated fractures still resulted in hospitalization or death in a certain percentage of patients.
JOURNAL OF DIABETES INVESTIGATION
(2021)
Article
Medicine, Research & Experimental
Chang Chu, Denis Delic, Jana Alber, Martina Feger, Yingquan Xiong, Ting Luo, Ahmed A. Hasan, Shufei Zeng, Mohamed M. S. Gaballa, Xin Chen, Lianghong Yin, Thomas Klein, Saban Elitok, Bernhard K. Kraemer, Michael Foeller, Berthold Hocher
Summary: This study using a rat AKI model confirmed the safety data from the EMPA-REG OUTCOME trial, indicating that empagliflozin may reduce AKI risk and have beneficial regulation of inflammation. These findings provide valuable insights for conducting clinical studies with AKI risk as the primary endpoint.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Health Care Sciences & Services
Jason T. Alexander, Erin M. Staab, Wen Wan, Melissa Franco, Alexandra Knitter, M. Reza Skandari, Shari Bolen, Nisa M. Maruthur, Elbert S. Huang, Louis H. Philipson, Aaron N. Winn, Celeste C. Thomas, Meltem Zeytinoglu, Valerie G. Press, Elizabeth L. Tung, Kathryn Gunter, Brittany Bindon, Sanjay Jumani, Neda Laiteerapong
Summary: SGLT2Is show durable reductions in cardiovascular risk factors compared to both placebo and other anti-hyperglycemic medications. Reductions in macrovascular complications and mortality were observed only in comparisons with placebo, with insufficient data for longer-term outcomes in comparisons with other anti-hyperglycemic medications. An increased risk of genital yeast infections was observed for both genders in comparisons with placebo and other anti-hyperglycemic medications.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
M. Donniacuo, A. De Angelis, M. Telesca, G. Bellocchio, M. A. Riemma, P. Paolisso, E. Cianflone, D. Torella, G. Castaldo, A. Capuano, K. Urbanek, L. Berrino, F. Rossi, D. Cappetta
Summary: Atrial fibrillation (AF) is a common arrhythmia with significant morbidity and mortality, characterized by pro-fibrotic signaling and abnormal Ca2+ handling at the atrial level. Anticoagulation, symptoms control, and management of risk factors are the primary focus of AF care. The restoration of sinus rhythm, atrioventricular synchrony, and improvement of atrial contribution to stroke volume are the goals of AF therapy. Epigenetic phenomena, such as DNA methylation, histone modifications, and noncoding RNAs, provide new insights into AF pathophysiology and potential targets for pharmacological interventions. In addition, sodium-glucose cotransporter 2 inhibitors (SGLT2i) show potential in modifying the epigenetic signature in cardiovascular diseases, suggesting a possible role in the onset and progression of AF. This review discusses the pathophysiology and management of AF, as well as the epigenetic mechanisms and the potential of SGLT2i in AF patients.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Sohee Park, Han Eol Jeong, Hyesung Lee, Seng Chan You, Ju-Young Shin
Summary: This study investigated the effects of SGLT2 inhibitors on acute heart failure in patients with type 2 diabetes. The results showed that initiating SGLT2 inhibitor treatment after an episode of acute heart failure was associated with a reduced risk of heart failure readmission and cardiovascular mortality.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Fang-Ju Lin, Chi-Chuan Wang, Chien-Ning Hsu, Chen-Yi Yang, Chih-Yuan Wang, Huang-Tz Ou
Summary: This study demonstrates the renoprotective benefit of real-world SGLT-2 inhibitor use regardless of patients' baseline kidney function.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Shinji Kishimoto, Yukihito Higashi, Takumi Imai, Kazuo Eguchi, Kazuo Fukumoto, Hirofumi Tomiyama, Koji Maemura, Atsushi Tanaka, Koichi Node
Summary: This study aimed to assess the impact of ipragliflozin, an SGLT2 inhibitor, on endothelial function in patients with type 2 diabetes over a 24-month period. The results showed that HbA1c levels significantly decreased in the ipragliflozin group but not in the control group after 24 months of treatment. However, there was no significant difference in the changes of HbA1c levels between the two groups. Additionally, there was no significant change in FMD values before and after treatment in both groups.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Cheng-Yang Hsieh, Sheng-Feng Sung
Summary: Chronic kidney disease (CKD) is a significant risk factor for stroke and cerebrovascular disease, yet the interaction between the brain and kidneys has received less attention compared to the interaction between the heart and kidneys. This article focuses on the potential of SGLT2 inhibitors, a class of oral anti-diabetic drugs, in preventing strokes and improving the cerebro-renal interaction, regardless of diabetes status. The authors propose the roles of baseline renal functions and dual inhibition of SGLT1/2 in stroke prevention, as well as the additional benefits of reducing atrial fibrillation and hemorrhagic stroke.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Medicine, Research & Experimental
Simeon I. Taylor, Bruce R. Leslie
JOURNAL OF CLINICAL INVESTIGATION
(2018)
Editorial Material
Endocrinology & Metabolism
Simeon I. Taylor, Richard D. DiMarchi
Editorial Material
Endocrinology & Metabolism
Simeon I. Taylor
Review
Medicine, Research & Experimental
Simeon I. Taylor, Zhinous Shahidzadeh Yazdi, Amber L. Beitelshees
Summary: Diabetes mellitus is a significant public health issue, with pharmacotherapy aiming to prevent complications. Clinical trials have shown that intensive glycemic control can slow the progression of complications, with some drugs also demonstrating cardiovascular benefits and slowed progression of diabetic kidney disease.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Editorial Material
Endocrinology & Metabolism
Scott J. Pilla, Zhinous Shahidzadeh Yazdi, Simeon I. Taylor
Article
Endocrinology & Metabolism
Simeon I. Taylor, May E. Montasser, Ashley H. Yuen, Hubert Fan, Zhinoosossadat Shahidzadeh Yazdi, Hilary B. Whitlatch, Braxton D. Mitchell, Alan R. Shuldiner, Ranganath Muniyappa, Elizabeth A. Streeten, Amber L. Beitelshees
Summary: This study aimed to identify genetic variants associated with the variability of drug responses to glucagon-like peptide-1 receptor agonists. The findings showed that these drugs increased insulin secretion and accelerated glucose metabolism in healthy volunteers. However, they had minimal effects on insulin sensitivity. These findings highlight the importance of personalized medicine in drug treatments.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Simeon I. Taylor, Hua-Ren Cherng, Zhinous Shahidzadeh Yazdi, May E. Montasser, Hilary B. Whitlatch, Braxton D. Mitchell, Alan R. Shuldiner, Elizabeth A. Streeten, Amber L. Beitelshees
Summary: This study confirmed the pharmacodynamic responses to SGLT2 inhibitors and their association with genetic variants. Canagliflozin (300 mg) was shown to cause acute changes in biomarkers such as plasma glucose, serum creatinine, and serum uric acid levels. Normalizing data relative to creatinine excretion will facilitate the inclusion of data from both males and females in future analyses.
DIABETES OBESITY & METABOLISM
(2023)
Letter
Endocrinology & Metabolism
Simeon I. Taylor
JOURNAL OF THE ENDOCRINE SOCIETY
(2020)
Article
Endocrinology & Metabolism
Jenny E. Blau, Sri Harsha Tella, Simeon I. Taylor, Kristina I. Rother
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2017)